Home/Pipeline/Acuitas AMR Gene Panel (ucp)

Acuitas AMR Gene Panel (ucp)

Urinary Tract Infection (UTI) pathogen & resistance detection

Development/RegulatoryUnder FDA Review

Key Facts

Indication
Urinary Tract Infection (UTI) pathogen & resistance detection
Phase
Development/Regulatory
Status
Under FDA Review
Company

About OpGen

OpGen's mission is to preserve the efficacy of antibiotics and improve patient outcomes by delivering rapid, precise diagnostic information to combat infectious diseases. Its core achievements include the FDA-cleared Acuitas AMR Gene Panel and the Unyvero multiplex PCR platform, which address critical needs in pneumonia, bloodstream, and urinary tract infections. The company's strategy integrates diagnostic testing with data analytics to support hospital antimicrobial stewardship and infection prevention programs, while its CapForce subsidiary represents a separate, non-core business initiative. OpGen faces the dual challenge of driving adoption in a competitive diagnostic market and achieving sustainable financial growth.

View full company profile